Ubs Group Ag Satsuma Pharmaceuticals, Inc. Transaction History

Ubs Group Ag

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.7 - $1.07 $1,270 - $1,942	1,815 New	1,815 $1,000
Q3 2022 Nov 10, 2022	SELL	$4.19 - $7.95 $73,605 - $139,657	-17,567 Reduced 99.85%	27 $0
Q2 2022 Aug 10, 2022	BUY	$2.59 - $4.3 $39,178 - $65,046	15,127 Added 613.17%	17,594 $73,000
Q1 2022 May 16, 2022	BUY	$3.78 - $5.32 $9,230 - $12,991	2,442 Added 9768.0%	2,467 $9,000
Q4 2021 Feb 14, 2022	BUY	$4.15 - $6.24 $103 - $156	25 New	25 $0
Q3 2021 Nov 15, 2021	SELL	$4.54 - $7.17 $13,642 - $21,545	-3,005 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$4.8 - $7.25 $6,172 - $9,323	1,286 Added 74.81%	3,005 $21,000
Q1 2021 May 12, 2021	BUY	$4.57 - $7.18 $1,846 - $2,900	404 Added 30.72%	1,719 $10,000
Q4 2020 Feb 11, 2021	BUY	$3.56 - $5.09 $1,306 - $1,868	367 Added 38.71%	1,315 $6,000
Q3 2020 Nov 12, 2020	SELL	$3.85 - $28.47 $1,867 - $13,807	-485 Reduced 33.85%	948 $4,000
Q2 2020 Jul 31, 2020	BUY	$16.01 - $34.69 $18,459 - $39,997	1,153 Added 411.79%	1,433 $41,000
Q1 2020 May 01, 2020	SELL	$14.53 - $30.69 $79,173 - $167,229	-5,449 Reduced 95.11%	280 $6,000
Q4 2019 Feb 14, 2020	BUY	$9.32 - $19.68 $48,240 - $101,863	5,176 Added 935.99%	5,729 $113,000
Q3 2019 Nov 14, 2019	BUY	$14.98 - $16.9 $8,283 - $9,345	553 New	553 $8,000

Ticker STSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,587,500
Description
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.